Myeloproliferative Disease: Dealing With a Diagnostic Dilemma
DOI:
https://doi.org/10.3126/njc.v5i1.42283Keywords:
Tuberculosis, Myeloproliferative disease, BCR-ABL fusion gene, (JAK 2) V617F mutationAbstract
Myeloproliferative neoplasms (MPNs) constitute a group of hematologic clonal diseases that affect one or more myeloid lineages with abnormal proliferation. It is rare disease entity and incidence is about 1.15 to 4.99/100 000 person-years among hematological neoplasms for all subtypes of MPNs combined. Patients who present with hepatosplenomegaly, hyperleukocytosis with monocytosis should have routine tests along with bone marrow morphology possibly biopsy, quantiferon TB Gold in tube test, Dengue fever IgM, IgG, NS-1 antigen, cytogenetics t(9;22), BCR cABL fusion gene, JAK-2 V617F, MPL mutations, CALR gene test done along with karyotyping and flowcytometry to evaluate and establish diagnosis towards management.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Nepalese Journal of Cancer
This work is licensed under a Creative Commons Attribution 4.0 International License.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as NJC and the authors are acknowledged.
Submission of the manuscript means that the authors agree to assign exclusive copyright to NJC. The aim of NJC is to increase the visibility and ease of use of open access scientific and scholarly articles thereby promoting their increased usage and impact.